PhRMA
NOVEMBER 21, 2022
Research has shown that 340B hospitals are more likely to prescribe more expensive medicines and significantly mark up the price of medicines. For example, 340B hospitals received nearly five times what they paid, on average, to acquire oncology medicines through 340B. These practices have implications for what patients pay out of pocket — and new research adds to the evidence.
Drug Topics
NOVEMBER 21, 2022
Israeli researchers find more than fivefold risk of developing systemic sclerosis among people with vitiligo.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmacy Times
NOVEMBER 21, 2022
Research also focuses on connection between oral hygiene and other chronic diseases, neurological disorders, pulmonary infections.
Pharmaceutical Technology
NOVEMBER 25, 2022
Artificial intelligence (AI) was seen as one of the top current investment priorities and was thought to continue to attract investment in the healthcare sector in the upcoming two years, according to GlobalData's latest report ‘Digital Transformation and Emerging Technology in the Healthcare Industry - 2022 Edition’. In this survey-based report tracker, digital media was prioritised as a top current investment target, with 53% of surveyed respondents confirming that their companies are currentl
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
PhRMA
NOVEMBER 22, 2022
Concerns about the cost of health care have led to calls for the use of health technology assessments or HTAs by the federal government. This would allow government agencies to make important decisions about patient access to health care based on their determination of the value of new tests and treatments.
Drug Topics
NOVEMBER 24, 2022
Take a look back at our most popular COVID-19 coverage for 2022.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Pharmacy Times
NOVEMBER 23, 2022
Study finds early career workers were more likely to disengage during the pandemic, such as by showing a lack of interest or becoming cynical about work.
PhRMA
NOVEMBER 22, 2022
Patients with chronic health conditions in Delaware are seeing a new wave of relief thanks to Governor John Carney, members of the Delaware legislature and more than 40 patient groups. The recently passed SB267 will make it easier for vulnerable patients to be able to afford their brand medications.
Drug Topics
NOVEMBER 23, 2022
Take a look back at our most popular diabetes coverage for 2022.
STAT
NOVEMBER 22, 2022
The updated Covid-19 boosters increase people’s protection against symptomatic infection from the coronavirus, according to some of the first estimates of how the shot is performing in the real world and in people, not just in lab experiments. What’s more, that protection was even stronger when people waited a longer period of time since their last dose of the original shot.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Pharmacy Times
NOVEMBER 21, 2022
Individuals with COVID-19 reinfections were twice as likely to die and three times more likely to be hospitalized than those who did not have COVID-19 multiple times.
European Pharmaceutical Review
NOVEMBER 21, 2022
The first-in-human gene therapy trial for heart failure patients with preserved ejection fraction (HFpEF) has been approved by the US Food & Drug Administration (FDA). SRD-001, the adenovirus associated virus (AAV)-based gene therapy is delivered to cardiac ventricular muscle cells via an intracoronary infusion system (produced by Sardocor, a clinical-stage gene therapy subsidiary of Medera), to increase the protein expression and functional activity of sarcoplasmic reticulum calcium ATPase
Drug Topics
NOVEMBER 23, 2022
In a recent study, racial minorities of an older age with non-classic cutaneous manifestations were more often to present with juvenile idiopathic inflammatory myopathies after COVID-19 infection.
STAT
NOVEMBER 22, 2022
The Food and Drug Administration on Tuesday approved the first gene therapy to treat people with hemophilia B, an inherited bleeding disorder. The one-time treatment, called Hemgenix, was developed by the Dutch biotech company UniQure and will be marketed by CSL Behring, an Australian pharmaceutical company.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Pharmacy Times
NOVEMBER 25, 2022
Pharmacists play a significant role in the comprehensive management of this condition through education, intervention, and monitoring.
Fierce Healthcare
NOVEMBER 21, 2022
House lawmakers press Biden admin to change latest surprise billing rule. rking. Mon, 11/21/2022 - 17:18.
Drug Topics
NOVEMBER 24, 2022
European research examines antibiotic exposure and its potential impact on future type 2 diabetes risk.
STAT
NOVEMBER 24, 2022
An experimental influenza vaccine developed using messenger RNA technology appears capable of inducing what should be a protective immune response against all known subtypes of flu, at least in animals. If the work is translated into humans it could turn out to be a version of a long-sought universal vaccine. This would not be a vaccine that would block all flu infections, nor would it replace the need for an annual flu shot.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Pharmacy Times
NOVEMBER 23, 2022
For patients with opioid use disorder, medication-assisted treatment programs are a clinically effective approach.
European Pharmaceutical Review
NOVEMBER 23, 2022
The US Food and Drug Administration (FDA) has approved Hemgenix (etranacogene dezaparvovec), the first gene therapy for adults with Haemophilia B (congenital Factor IX deficiency) who currently use Factor IX prophylaxis therapy, or have current or historical life-threatening haemorrhage, or have repeated, serious spontaneous bleeding episodes. Standard treatment for the condition involves replacing the missing or deficient clotting factor to improve the body’s ability to stop bleeding and promot
Fierce Healthcare
NOVEMBER 23, 2022
Google rolls out search features that aim to make it easier to sign up for Medicaid, Medicare. pminemyer. Wed, 11/23/2022 - 11:12.
STAT
NOVEMBER 22, 2022
Flu season is underway. RSV is putting record numbers of children in hospitals. And health professionals are gearing up for another Covid winter. With so many potential viruses in play, it would be helpful if Americans had a way to distinguish between different ailments at home. And when it comes to the flu in particular, at-home testing could help telehealth doctors decide when it makes sense to prescribe treatments like Paxlovid and Tamiflu, which need to be administered within a specific time
Pharmacy Times
NOVEMBER 21, 2022
New system combines computational and experimental techniques to map evolutionary cancer lineages in their natural habitat of human tissue.
PharmaVoice
NOVEMBER 22, 2022
How Boston became the biotech capital of the U.S., and is now preparing for the next era of life sciences growth.
Fierce Healthcare
NOVEMBER 22, 2022
Advocacy groups press FTC to probe GPOs' role in supply chain shortages. rking. Tue, 11/22/2022 - 16:21.
pharmaphorum
NOVEMBER 25, 2022
There are approximately 7,000 different types of rare disease and researchers estimate that there are more than 300 million people worldwide living with such a condition, according to the National Institutes of Health (NIH). However, only 5% of rare diseases are estimated to have at least one approved treatment, known as “orphan” therapies. A rare disease is any disease that affects a small percentage of the population.
Pharmacy Times
NOVEMBER 24, 2022
Legislation expands protection of original 1965 act to individuals younger than 60 years.
Fierce Pharma
NOVEMBER 23, 2022
Sporting a $3.5M price tag, CSL and uniQure's hemophilia B gene therapy crosses FDA finish line. zbecker. Wed, 11/23/2022 - 10:10.
Fierce Healthcare
NOVEMBER 20, 2022
Walgreens plots 'aggressive' strategy to build out healthcare services, CEO Roz Brewer says. hlandi. Sun, 11/20/2022 - 18:20.
pharmaphorum
NOVEMBER 23, 2022
The US regulator has started a priority, six-month review of Takeda’s dengue fever vaccine TAK-003 – tipped as a potential blockbuster product – making a decision likely in the first half of 2023. The Japanese pharma said it has filed for approval of TAK-003 with the FDA for the prevention of dengue disease caused by any dengue virus serotype in individuals aged four through 60.
Pharmacy Times
NOVEMBER 23, 2022
As a new year approaches, pharmacists have so much to look back on and be grateful for, and a world of opportunity in front of them. Here are a few things to be ready for right away in 2023.
Fierce Pharma
NOVEMBER 23, 2022
On a roll, Takeda's dengue vaccine shifts into FDA's fast review lane. kdunleavy. Wed, 11/23/2022 - 09:35.
Fierce Healthcare
NOVEMBER 23, 2022
ACA signups top 3M since start of open enrollment, a 17% bump compared to last year. rking. Wed, 11/23/2022 - 11:58.
Expert insights. Personalized for you.
262 
Let's personalize your content